Company registration number 10571317 (England and Wales)
CELLOPATH LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
PAGES FOR FILING WITH REGISTRAR
CELLOPATH LTD
COMPANY INFORMATION
Directors
Dr PD Barrett
Mrs K Barrett
Company number
10571317
Registered office
Little Dene
Elvaston Park Road
Hexham
Northumberland
NE46 2HT
Accountants
RMT Accountants & Business Advisors Ltd
Gosforth Park Avenue
Newcastle upon Tyne
NE12 8EG
Bankers
Handelsbanken
43 Old Elvet
Durham
DH1 3HN
CELLOPATH LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
CELLOPATH LTD
BALANCE SHEET
AS AT
31 JANUARY 2026
31 January 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible fixed assets
4
2,353
2,595
Investment properties
5
363,909
363,909
366,262
366,504
Current assets
Cash at bank and in hand
210,135
213,104
Creditors: amounts falling due within one year
6
(120,397)
(149,518)
Net current assets
89,738
63,586
Total assets less current liabilities
456,000
430,090
Provisions for liabilities
(645)
(706)
Net assets
455,355
429,384
Capital and reserves
Called up share capital
7
1
1
Share premium account
3
3
Profit and loss reserves
455,351
429,380
Total equity
455,355
429,384
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
For the financial year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 17 September 2026 and are signed on its behalf by:
Dr PD Barrett
Director
Company Registration No. 10571317
CELLOPATH LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
- 2 -
1
Accounting policies
Company information
Cellopath Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Little Dene, Elvaston Park Road, Hexham, Northumberland, NE46 2HT.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for medical services provided in the normal course of business.
1.3
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Fixtures, fittings and equipment
15% reducing balance
1.4
Investment properties
Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at the reporting end date. Changes in fair value are recognised in profit or loss.
1.5
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).
1.6
Cash at bank and in hand
Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.
1.7
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
CELLOPATH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 3 -
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
1.8
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.9
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2026
2025
Total
3
3
CELLOPATH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 4 -
3
Tax on profit
2026
2025
£
£
Current tax
UK corporation tax on profits for the current period
6,721
31,267
Deferred tax
Origination and reversal of timing differences
(61)
(114)
Total tax charge
6,660
31,153
4
Tangible fixed assets
Fixtures, fittings and equipment
£
Cost
At 1 February 2025
6,807
Additions
225
Disposals
(160)
At 31 January 2026
6,872
Depreciation
At 1 February 2025
4,212
Depreciation charged in the year
420
Eliminated in respect of disposals
(113)
At 31 January 2026
4,519
Carrying amount
At 31 January 2026
2,353
At 31 January 2025
2,595
CELLOPATH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 5 -
5
Investment property
2026
£
Fair value
At 1 February 2025 and 31 January 2026
363,909
Investment property comprises of the 1 Meadow Way purchase price plus legal fees.
The directors believe that the carrying amount of the investment property approximates to its fair value.
Although no formal revaluation has been undertaken at the year end, when taking the length of time the
company has owned the property and current market conditions into consideration, it is unlikely that the
carrying value is significantly different to fair value.
6
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
2,261
4,102
Corporation tax
6,721
31,267
Other creditors
111,415
114,149
120,397
149,518
7
Called up share capital
2026
2025
£
£
Ordinary share capital
Authorised
100 ordinary shares of 1p each
1
1
Issued and fully paid
100 ordinary shares of 1p each
1
1
1
1
8
Related party transactions
The following amounts were outstanding at the reporting end date:
2026
2025
Amounts due to related parties
£
£
Director
111,415
114,149
There are no set terms as to the repayment of this balance and no interest accruing thereon.